111P - Pharmacist led proactive follow-up algorithm for advanced EGFR positive NSCLC patients on afatinib

Date 07 May 2017
Event ELCC 2017
Session Poster Display Session
Topics Non-Small-Cell Lung Cancer, Locally Advanced
Cancer Immunology and Immunotherapy
Lung and other Thoracic Tumours
Presenter Parneet Cheema
Citation Annals of Oncology (2017) 28 (suppl_2): ii28-ii51. 10.1093/annonc/mdx091
Authors P.K. Cheema1, A. Thawer2, J. Leake2, S.Y. Cheng1, S. Khanna3, J.C. Victor4
  • 1Medical Oncology And Hematology, Sunnybrook Odette Cancer Center, Sunnybrook HSC, M4N 3M5 - Toronto/CA
  • 2Sunnybrook Odette Cancer Center, Sunnybrook HSC, M4N 3M5 - Toronto/CA
  • 3Mackenzie Health Hospital, L4C 4Z3 - Toronto/CA
  • 4Institute Of Health Policy Management And Evaluation, University of Toronto, M5T 3M6 - Toronto/CA

Abstract

Background

Afatinib is a standard first-line therapy for advanced EGFR positive NSCLC. We implemented a pharmacy led proactive follow-up algorithm for pts prescribed afatinib to identify and manage early adverse events (AEs) (Table). Management of AEs was standardized.

Methods

This was a retrospective chart review of all advanced EGFR positive NSCLC pts at the Sunnybrook Odette Cancer Centre from April 1, 2015 to July 31, 2016 that received afatinib following institution of our algorithm. This study evaluated the impact of our algorithm and characteristics of real world AEs.

Results

We included 33 pts. Median age was 64 and 55%, 79%, 59%, 27% and 88% were female, PS < 2, Asian, smokers, and treated as 1st line, respectively. Median follow up was 249 days (d). Median time on afatinib was 157 d (IQR: 27 to 304). Prophylactic use of topical hydrocortisone/clindamycin was 55% and 46% for an oral tetracycline. All pts had 1 drug related AE, 18% were grade 3/4. Most common AEs were diarrhea 88%, rash 82%, stomatitis 58%, paronychia 46%, nausea 39% and fatigue 39%. Median time to 1st drug related AE was 17 d (IQR: 7 to 126), with early median time to onset of diarrhea 8 d, stomatitis 13 d, rash 15 d, fatigue 18 d and nausea 25 d and late onset of paronychia 75 d, transaminitis 114 d and anorexia 133 d. Median dose of afatinib was 40 mg/daily, 34% of pts had > or = 1 dose reduction and 9% discontinued afatinib due to AEs. Proactive calls identified 37% of all drug related AEs, 33% of grade 3/4 AEs, 58% of first drug related AEs and identified 2 patients that were noncompliant. Only 3% of AEs were identified by an ER visit/urgent clinic visit.rnTable: 111P

Phamacist led follow-up algorithm for pts prescribed afatinib

rnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrn rnrn
Time on drugDay 1Day 5Day 10Day 14Day 17
InterventionVisit with pharmacyProactive pharmacy callProactive pharmacy callRoutine clinic visit with medical oncologyProactive pharmacy call
Variables assessedPatient education of side effects and consent obtained for proactive callsAdherence Rash Diarrhea StomatitisAdherence Rash Diarrhea Stomatitis Paronychia Nausea FatigueClinical assessment and laboratory monitoring of CBC, creatinine and liver function testsAdherence Rash Diarrhea Stomatitis Paronychia Nausea Fatigue Anorexia
rn

Conclusions

Our algorithm resulted in early identification and management of AEs with a low rate of urgent assessments and discontinuation due to toxicity while maintaining the ideal dose of afatinib. This algorithm provides a tool for centres prescribing afatinib.

Clinical trial identification

Legal entity responsible for the study

Dr. Parneet Cheema, PI and Sunnybrook Health Sciences Centre

Funding

Boehringer Ingelheim

Disclosure

P.K. Cheema: Advisory board and research grants: Boehringer Ingelheim. A. Thawer: Advisory board and research grant: Boehringer Ingelheim. S.Y. Cheng, S. Khanna: Advisory board: Boehringer Ingelheim. All other authors have declared no conflicts of interest.